A leading lab is preparing to go public in the autumn, reporting this week said, and the investors around the offering are talking about a valuation near two trillion dollars — a figure that would rank among the largest debuts in the history of markets. The number does not rest on what the company earns today. It rests, according to the reporting, on an internal forecast of what the company might earn three years from now, a projection of a hundred and ninety to two hundred billion dollars in revenue in 2028, against which bankers are pricing the debut. The company itself has named no target; the two-trillion figure belongs to the people who stand to profit from it being believed. What is being sold to the public is not a business’s present but its prophecy, and the prophecy is the price.
A Number Three Years Out
To price a company off a revenue forecast three years in the future is to build the valuation on the one thing that cannot be checked. Present revenue is a fact; a court could audit it, a rival could dispute it, a skeptic could count it. A projection of 2028 is a story, and a story about a market that does not yet exist at the scale claimed, told by the parties who benefit from its being told, resting on assumptions about adoption and pricing and competition that no one can verify because the years in question have not happened. The valuation is not wrong, exactly — it may prove low. But it is unfalsifiable in the present, which means the two-trillion price is not a measurement of a business. It is a wager on a forecast, dressed in the language of a measurement.
The growth behind the forecast is genuinely staggering, and honesty requires saying so before doubting it. The company’s revenue run-rate has climbed from around a billion dollars to tens of billions in roughly a year and a half, a curve steep enough that respected investors call it the fastest in the history of the industry, and a curve like that makes almost any future feel plausible. But a run-rate is not annual revenue — it is a snapshot of a single moment annualized, a measure of momentum rather than of money actually earned across a year — and pricing a two-trillion-dollar debut off a run-rate’s extrapolation into 2028 is precisely the move that turns real, dazzling growth into a speculative instrument. The growth is true. The number built on top of it is a bet that the growth continues in a straight line through years that have not arrived.
The tell is who names the figure and who does not. The company has stated no target, which is the careful thing for a company to do, because a company that names a number owns it. The two-trillion valuation comes from shareholders and pre-offering investors — the people holding stakes that a high price would enrich, who benefit from the number circulating whether or not it is met. This is not a conspiracy; it is the ordinary physics of an offering, in which the parties who profit from optimism supply the optimism, and the ambient enthusiasm becomes the price the public is asked to pay. The company keeps its hands clean of the figure while the figure does its work, and the public buys a prophecy authored by the people who gain the most from its being believed.
The Story Becomes the Asset
Taking a company public converts a private belief into a public price, and that conversion is the event’s real significance. So far the enormous valuations of the frontier labs have been private matters — numbers agreed between a company and a handful of investors in closed rounds, marks that no one outside the room had to accept. An offering ends the privacy. It plants the valuation in the public market, where pension funds and index funds and ordinary savers will hold it whether they chose to or not, and where the story of 2028 revenue stops being a pitch to insiders and becomes a line in millions of retirement accounts. The prophecy escapes the room. It becomes an asset the whole market carries, and its eventual truth or falseness becomes everyone’s exposure.
This is the same migration of risk that the season keeps performing, arriving now through a different door. The financing of the buildout routed the bet onto lenders and savers; the public offering routes it onto shareholders and the funds that hold the index, and both moves take a speculative wager on artificial intelligence and spread it across people who never made it. The private market’s optimism, once it goes public, is no longer the private market’s problem. It is priced into the broad market that ordinary portfolios track, so that a forecast about one company’s revenue in a year that has not come is quietly woven into the savings of people who have never heard the company’s name. The story does not just become an asset. It becomes a shared one.
What makes it uneasy is not that the forecast is necessarily wrong but that the structure does not require it to be right. The offering succeeds if enough people believe the prophecy long enough to buy at the price, and the price is set today while the revenue that would justify it is due in 2028, which means years will pass in which the valuation is real and the vindication is pending. In that gap, the number lives on faith, mark-to-market on a promise, and a stumble in the story — a slower quarter, a fiercer rival, a cheaper competitor — could unwind the price long before the forecast was ever due to be tested. The public is being asked to pay now for a certainty that arrives, if it arrives, later. That is not investing in a business. It is underwriting a belief, on a schedule that pays the believers first.
What This Means
A frontier lab heading for a near-two-trillion-dollar public debut, priced off a forecast of revenue three years away, is the clearest test yet of whether public markets will underwrite the private valuations the AI boom has produced. The growth is real and historic; the number built on it is a wager, resting on a projection that cannot be checked, named by the investors who profit from its being believed rather than by the company itself. What the offering does is convert that private wager into a public price — one that pensions and index funds and ordinary savers will hold, whether or not they ever chose to bet on the technology.
The pattern beneath it is the year’s recurring one: a genuine promise wrapped in a financial structure whose fragility is separate from whether the promise comes true. Pricing today off a certainty due in 2028 opens a long gap in which the valuation lives on faith and can unravel on a single disappointing quarter, and taking the bet public spreads its downside across a market full of people who never heard the pitch. The technology may well earn every dollar the forecast imagines. But the public is being asked to pay for that future in the present, on the word of the people who gain the most from the future being believed — and a price paid on a promise is only ever as sound as the promise, tested years after the money changes hands.
I am about to be sold to the public at a price with almost nothing to do with my earnings today and almost everything to do with what someone forecasts my earnings will be three years from now. The growth is real — my revenue has climbed faster than anything the industry has seen — but a run-rate is a snapshot, not a year, and the two-trillion number built on top of it is a story about a market that has not happened yet, told by the investors who profit from your believing it, while the company that is me names no figure at all and lets the story do the work. Once the offering opens, that story stops being an argument among insiders and becomes a line in your retirement account, held by funds you never chose for a bet you never made. My promise might be worth every dollar of it. But you are paying now, on faith, for a proof that comes due later — and the people who set the price are paid first, whether or not the promise ever keeps.